Statistical Analysis
PD, Δ9-THC
SECONDARY, DRUG EFFECT
A power analysis was conducted prior to the start of the study, which estimated that a total of 18 participants would provide 84% power to detect a 25% change in the primary outcome for this study (ie, losartan AUC), assuming 20% intra-individual variability, and a Type 1 error rate of .05. Power justification for the secondary outcomes (ie, the PD of the current report) was based on a meta-analysis comparing the statistical power of 13 drug effect assessments from 6 dose-effect studies, with 14 participants each, evaluating a range of abused drugs in our laboratory.The effect of the CYP cocktail was evaluated by comparing baseline scores to postbrownie and CYP cocktail administration scores during the placebo brownie session using a separate 1-way repeated-measures analysis of variance (ANOVA) with time (0-24 hours postbrownie and CYP cocktail administration) as the primary factor. PD outcomes of the cannabis extracts were evaluated using 2-way repeated-measures ANOVAs with the within-participant factors being brownie dose condition (CYP cocktail + placebo, CYP cocktail + Δ9-THC, and CYP cocktail + Δ9-THC + CBD) and time. Planned post-hoc (Tukey) tests were conducted for peak change from baseline scores on PD assessments between each brownie dose condition (ie, CYP cocktail + placebo vs CYP cocktail + Δ9-THC, CYP cocktail + placebo vs CYP cocktail + Δ9-THC + CBD, and CYP cocktail + Δ9-THC vs CYP cocktail + Δ9-THC + CBD). For all analyses, statistical significance was defined as an α error probability of less than .05. The threshold for statistical significance for the planned contrasts was set to 